Get solid data to base decisions on

Contract research services within Diabetic Complications

Gubra has long-standing experience of conducting preclinical diabetic nephropathy studies in a variety of different rodent models of both type 1 and type 2 diabetes. We complement the models with novel histology imaging endpoints and biomarker endpoints.

Gubra offers consultancy and preclinical models within cardiovascular disease including heart failure and atherosclerosis.

Our scientific expertise within diabetes, combined with our experience within micro- and macrovascular models, provide solid data on which to base decisions.

We offer:

  • Diabetic nephropathy models
  • Cardiovascular disease models (cardiomyopathy, heart failure and hypertension)
  • Glomerular filtration rate and metabolic caging for urine sampling
  • Advanced histology, image analysis and 3D imaging of heart and kidney
  • Continuous (24h) monitoring of heart rate and ECG
  • Rat echocardiography
  • RNA sequencing and bioinformatics

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Niels Vrang

Co-founder, Chairman of the board
niels@gubra.dk
+45 3152 2651

Get in touch

Contact us

T1D rat DN model: Gubra PxUNx rat

Novel diabetic nephropathy model displaying progressive albuminuria, glomerulosclerosis and renal fibrosis. Diabetes-induction with no side-effects from toxic compounds. The partial pancreatectomy combined with unilateral nephrectomy permits a short duration: 11 weeks

Novel Rat Model of Diabetic Nephropathy Displaying Tubular Fibrosis and Glomerular Alterations

T2D mouse DN model: db/db UNx

Refinement of the well-described db/db model of diabetic nephropathy. Unilateral nephrectomy permits shorter duration (18 weeks of age), where animals develop albuminuria and glomerular hypertrophy. Pharmacological effects quantified by advanced image analysis, stereology or 3D imaging

Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy

Diabetic rat model with myocardial alterations

Our research has shown that the db/db mouse model is preferable for evaluating the potential proliferative effects of various interventions (pharmacological and non-pharmacological).

Novel ‘Dual Hit’ Rat Model of Diabetic Cardiomyopathy

“Gubra is a highly competent partner in execution of – also more complicated – preclinical studies. The long term experience and the deep scientific competence of Gubra partners adds value to the studies and is a guaranty for trustworthy results.“

Dr. Michael Mark
Vice President | Boehringer Ingelheim

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

info@gubra.dk
+45 3152 ­2650